EyePoint, Inc.

EYPT Healthcare Biotechnology

EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024.

Revenue
−90.5%
EPS
−28.2%
Free cash flow
+0.41%

Quarter to June 2026, against a year earlier

0.36 0.00 0.00%
Market cap
$30.7M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
8.46
Beneish M
−2.16
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
188.82 249.50 328.66 216.11
Total non-current assets
39.37 38.71 35.34 35.59
Total Assets
228.19 288.22 364.00 251.70
Total current liabilities
41.94 37.46 37.02 30.09
Total non-current liabilities
19.84 20.29 20.86 21.42
Total liabilities
61.78 57.75 57.88 51.51
Common Equity (Total)
166.41 230.47 306.11 200.18
Shareholders Equity (Total)
166.41 230.47 306.11 200.18

Show all line items

In millions of $ except per-share values · columns are period end dates